Dr Peter Fellner was appointed Chairman in May 2009, having served as a director since November 2005. He is also Chairman of Vernalis plc, Optos plc, Biotie Therapies Corp. and Ablynx nv. In addition he serves as a director of the global biopharmaceutical company UCB SA. He is a member of the Novo A/S Advisory Group. Dr Fellner previously served as Chairman of Celltech Group plc from 2003 to July 2004, having been CEO from 1990 onwards. Before joining Celltech he was CEO of Roche UK from 1986 to 1990. More recently he served as Chairman of Acambis plc from 2006 until 2008, and of Premier Research Group plc from 2007 to 2008. He was also Vice Chairman of Astex Pharmaceuticals, Inc from 2011 to 2013 and served as a director of QinetiQ Group plc and Evotec AG. Peter is Chairman of the Nomination Committee.
Jonathan Glenn was appointed Chief Executive in December 2007 and before that had been Group Finance Director since September 2006. Prior to joining Consort Medical plc, Jonathan was Global Head of Finance at Celltech Group plc and later Chief Financial Officer of Akubio Ltd, a Cambridge based developer of instrumentation for the life sciences industry. He is a member of the Institute of Chartered Accountants in England and Wales. Jonathan is a member of the Nomination Committee.
Richard Cotton was appointed Chief Financial Officer in June 2012. He is a Chartered Management Accountant. From 2008 to 2011 he was Group Finance Director of Vitec Group plc, from 2005 to 2008 Group Finance Director at Wagon, and from 2001 to 2005 Group Finance Director of McLeod Russell plc.
Steve Crummett was appointed as a non executive director in June 2012. Steve is currently the Finance Director of Morgan Sindall Group plc. Previously Steve was Group Finance Director of Filtrona plc from 2008 to 2012 and from 2003 to 2006, Steve was Group Director, Mergers & Acquisitions of the FTSE 100 company Exel plc. Steve qualified as a Chartered Accountant with Arthur Andersen. Steve is Chairman of the Audit Committee and a member of the Remuneration Committee and the Nomination Committee.
Ian Nicholson was appointed as a non executive director in June 2012. He is also Chairman of Bioventix Ltd, a diagnostics company, Chief Executive Officer of F2G Ltd, a UK-based antifungal drug discovery and development company,a Non-executive Director of Symphogen A/S, an antibody therapeutics company and Clinigen Group plc a specialty pharmaceuticals and services business, and also an Operating Partner at Advent Life Sciences. From 2004 to 2012 Ian was Chief Executive of Chroma Therapeutics Limited, a drug discovery and development company and from 2000 to 2004 Ian was Senior Vice President, Business Development at Celltech Group plc, then the UK's largest biotechnology company. He has extensive experience in licensing, mergers and acquisitions, and market development in the UK, Europe and the US. Ian is Chair of the Corporate Responsibility Committee and a member of the Nomination Committee.
Dr William Jenkins was
appointed as a non-executive director in May 2009 and is Principal of William
Jenkins Pharma Consulting. William is a non-executive director of Ablynx nv
& Allecra Therapeutics GmbH. He is also an ad hoc member of the board of
Evotec AG and a member of their Scientific Advisory Board as well as a member
of the Scientific Advisory board of BB Biotech Ventures and a member of the
Strategic Advisory Board of Chiesi Farmaceutici SpA. William has been advising
a wide range of pharma and biotech companies and investment and venture capital
firms in the healthcare sector since 1999. He was formerly head of Worldwide
Clinical and Regulatory Affairs for Novartis Pharma AG and Ciba Geigy AG before
that and previously held a similar senior position with Glaxo. William is the
Senior Independent Director, Chair of the Remuneration Committee and a member
of the Nomination Committee.
Andrew was appointed as a non executive director on 14 July 2014. Andrew Hosty is Chief Operating Officer at Morgan Advanced Materials plc, an appointment he has held since February 2013. Prior to this Andrew was Chief Executive Officer of Morgan Ceramics and joined the Morgan Advanced Materials plc Board in July 2010. Before this he held a number of senior positions within Morgan Advanced Materials. Andrew is also a non executive director of British Ceramic Research Limited. Previously Andrew was a non executive director of Fiberweb plc from 2012 to 2013 and President of the British Ceramics confederation from 2003 to 2005.
Charlotta Ginman was appointed a non-executive director in February 2015.
Ms Ginman is a non-executive Director of Kromek Group plc, where she is the current Chairman of the Audit Committee, and is also a non-executive Director of Pacific Assets Trust plc and Polar Capital Technology Trust plc. Until 21 August 2014 Ms Ginman was a non-executive director of Wolfson Microelectronics plc.
Ms Ginman qualified as a Chartered Accountant at Ernst & Young before spending a career in investment banking and commercial organisations, principally in technology-related businesses. Ms Ginman began her career at Ernst & Young joining in 1989, and was then appointed to a series of senior roles in investment banking with JP Morgan, Deutsche Bank and UBS both in London and Singapore. Ms Ginman has also held senior roles within Nokia Corporation, including acting as Chief Financial Officer of its luxury mobile phone division Vertu Corporation Limited. Ms Ginman oversaw the successful sale of Vertu Corporation to a private equity group in 2012.
Ms Ginman is a member of the Nomination Committee and the Audit Committee.'